Biolegend, 502201, Purified anti-human GM-CSF Antibody, 50μg

Granulocyte/macrophage - colony stimulating factor (GM-CSF) is a hematopoietic factor that is produced by activated T cells, B cells, mast cells, macrophages, fibroblasts and endothelial cells. In addition to supporting colony formation of granulocyte/macrophage progenitors, GM-CSF is a growth factor for erythroid, megakaryocyte and eosinophil progenitors.
50μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli -expressed, recombinant human GM-CSF
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: ELISA Capture - Quality testedIP, WB - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 2-6 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of GM-CSF recombinant protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: ELISA or ELISPOT Capture1-6: The Purified BVD2-23B6 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD2-21C11 antibody (Cat. No. 502304) as the detecting antibody. The Ultra-LEAF™ Purified antibody is suggested for ELISPOT capture.Neutralization1-4: The Ultra-LEAF™ Purified antibody (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human GM-CSF bioactivity (Cat. Nos. 502205 - 502210).Additional reported applications (for the relevant formats) include: immunoprecipitation3 and Western blotting.Note: For testing human GM-CSF in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. Nos. 432001 and 432004) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Bacchetta R, et al. 1990. J. Immunol. 144:902. Kita H, et al. 1991. J. Exp. Med. 174:745. Abrams J, et al. 1992. Immunol. Rev. 127:5. Abrams J, et al. 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker New York. p.133. Mahanty S, et al. 1992. J. Immunol. 148:3567. Klinman D, et al. 1994. Curr. Prot. Immunol.. John Wiley and Sons New York. Unit 6.19.
Product Citations: Matsumoto T, et al. 2015. J Asthma Allergy. 29:8. PubMed Takeuchi S, et al. 2015. Cancer Res . 75: 2629 - 2640. PubMed
RRID: AB_315211 (BioLegend Cat. No. 502201) AB_315212 (BioLegend Cat. No. 502202)
Structure: Cytokine; 22 kD (Mammalian)
Bioactivity: Growth/development granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors
Cell Sources: T cells, macrophages, fibroblasts, endothelial cells, mast cells
Cell Targets: Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts
Receptors: Heterodimer GM-CSFR α subunit (CDw116); β-subunit (CDw131) which is also shared the IL-3 and IL-5 receptor α chains
Biology Area: Cell Biology, Stem Cells
Molecular Family: Cytokines/Chemokines, Growth Factors
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Demetri G, et al. 1991. Blood 78:2791. 3. Fan D, et al. 1991. In vivo 5:571. 4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.
Regulation: Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans
Gene ID: 1437
UniProt: View information about GM-CSF on UniProt.org
Clone: BVD2-23B6
Regulatory Status: RUO
Other Names: Granulocyte/macrophage colony-stimulating factor, CSF-α, Pluripoietin-α, Eosinophil colony stimulating factor (Eo-CSF), Burst promoting activity (BPA)
Isotype: Rat IgG2a, κ